Literature DB >> 30069769

Afatinib.

Helga Wecker1, Cornelius F Waller2.   

Abstract

Afatinib (BIBW 2992, US: GilotrifTM, other countries: Giotrif©) is an irreversible blocker of the ErbB family, acting at the tyrosine kinases of these proteins. In 2013, it was approved by the FDA and the EMA for the treatment of adults with advanced, EGFR mutation-positive non-small-cell lung cancer. Further investigations for the treatment of many other tumors with afatinib, e.g., HNSCC and breast cancer, are ongoing.

Entities:  

Keywords:  Afatinib; EGFR; Mutation; NSCLC; Solid tumors

Mesh：

Substances：

Year:  2018        PMID： 30069769     DOI： 10.1007/978-3-319-91442-8_14

Source DB:  PubMed          Journal:  Recent Results Cancer Res        ISSN： 0080-0015


  10 in total

1.  Effects of Afatinib on Development of Non-Small-Cell Lung Cancer by Regulating Activity of Wnt/β-Catenin Signaling Pathway.

Authors:  Yue Wu; Jiajing Zhang; Changping Yun; Chenchen Dong; Ye Tian
Journal:  Comput Math Methods Med       Date:  2022-06-28       Impact factor: 2.809

2.  Effects of rifampicin on the pharmacokinetics of alflutinib, a selective third-generation EGFR kinase inhibitor, and its metabolite AST5902 in healthy volunteers.

Authors:  Yun-Ting Zhu; Yi-Fan Zhang; Jin-Fang Jiang; Yong Yang; Li-Xia Guo; Jing-Jing Bao; Da-Fang Zhong
Journal:  Invest New Drugs       Date:  2021-01-27       Impact factor: 3.651

3.  Afatinib for Advanced Non-small Cell Lung Cancer in a Case With an Uncommon Epidermal Growth Factor Receptor Mutation (G719A) Identified in the Cerebrospinal Fluid.

Authors:  Chunhua Ma; Chuoji Huang; Dongjiang Tang; Xin Ye; Zhi Li; Renzhong Liu; Ning Mu; Jing Li; Rong Jiang; Juncheng Zhang
Journal:  Front Oncol       Date:  2019-07-23       Impact factor: 6.244

Review 4.  Current Approaches in NSCLC Targeting K-RAS and EGFR.

Authors:  Veronica Aran; Jasminka Omerovic
Journal:  Int J Mol Sci       Date:  2019-11-14       Impact factor: 5.923

5.  EGFR (p. G719A+L747V)/EML4-ALK Co-alterations in Lung Adenocarcinoma with Leptomeningeal Metastasis Responding to Afatinib Treatment: A Case Report.

Authors:  Zhiqin Lu; Xia Wang; Yuxi Luo; Jianping Wei; Zhimin Zeng; Qiang Xiong; Jing Cai; Anwen Liu
Journal:  Onco Targets Ther       Date:  2021-04-23       Impact factor: 4.147

Review 6.  Overview of New Treatments with Immunotherapy for Breast Cancer and a Proposal of a Combination Therapy.

Authors:  Miguel Angel Galván Morales; Raúl Barrera Rodríguez; Julio Raúl Santiago Cruz; Luis M Teran
Journal:  Molecules       Date:  2020-12-02       Impact factor: 4.411

Review 7.  Synthetic Heterocyclic Derivatives as Kinase Inhibitors Tested for the Treatment of Neuroblastoma.

Authors:  Francesca Musumeci; Annarita Cianciusi; Ilaria D'Agostino; Giancarlo Grossi; Anna Carbone; Silvia Schenone
Journal:  Molecules       Date:  2021-11-23       Impact factor: 4.411

8.  Afatinib treatment response in advanced lung adenocarcinomas harboring uncommon mutations.

Authors:  Teng Li; Shouzheng Wang; Jianming Ying; Yan Wang; Xingsheng Hu; Xuezhi Hao; Ziyi Xu; Puyuan Xing; Junling Li
Journal:  Thorac Cancer       Date:  2021-09-21       Impact factor: 3.500

9.  The Presence of EGFR T790M in TKI-Naïve Lung Cancer Samples of Patients Who Developed a T790M-Positive Relapse on First or Second Generation TKI Is Rare.

Authors:  Weiting Li; Klaas Kok; Geok Wee Tan; Pei Meng; Mirjam Mastik; Naomi Rifaela; Frank Scherpen; T Jeroen N Hiltermann; Harry J M Groen; Anthonie J van der Wekken; Anke van den Berg
Journal:  Cancers (Basel)       Date:  2022-07-19       Impact factor: 6.575

10.  CDKN2A-mediated molecular subtypes characterize the hallmarks of tumor microenvironment and guide precision medicine in triple-negative breast cancer.

Authors:  Tianyi Cheng; Yingyi Wu; Zhiyu Liu; Yi Yu; Shixue Sun; Min Guo; Baoqing Sun; Chen Huang
Journal:  Front Immunol       Date:  2022-08-16       Impact factor: 8.786
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.